| Popat, Sanjay |
| Active, not recruiting | 3 | 401 | Europe | Carboplatin, Carboplatin Accord, Pemetrexed, Alimta, Bevacizumab, Avastin, Atezolizumab, Tecentriq, RO5541267 | ETOP IBCSG Partners Foundation, Hoffmann-La Roche | Pleural Mesothelioma Malignant Advanced | 09/23 | 03/25 | | |
ADOPT-lung, NCT06284317: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients with Early-stage, Operable, Non-small Cell Lung Cancer. |
|
|
| Recruiting | 3 | 290 | Europe, RoW | Adjuvant durvalumab | ETOP IBCSG Partners Foundation, AstraZeneca AG Switzerland | Non Small Cell Lung Cancer | 10/29 | 03/30 | | |
| Active, not recruiting | 2 | 37 | Europe | Nintedanib, Placebo | European Organisation for Research and Treatment of Cancer - EORTC | Malignant Pleural Mesothelioma | 03/24 | 03/24 | | |
| Recruiting | 2 | 68 | Europe | Adagrasib | ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc. | NSCLC Stage IV, KRAS P.G12C | 10/25 | 03/26 | | |
| Recruiting | 2 | 60 | Europe | Amivantamab, Lazertinib, Zirabev | ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals | Non Small Cell Lung Cancer | 03/26 | 09/26 | | |
AMBER, NCT06068153: AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC |
|
|
| Withdrawn | 2 | 47 | Europe | Sotorasib, Lenvatinib | ETOP IBCSG Partners Foundation, Amgen, Eisai Inc. | Metastatic Non Small Cell Lung Cancer, KRAS G12C | 09/26 | 12/26 | | |
BOUNCE, NCT05718297: Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 44 | Europe | Brigatinib, Durvalumab | ETOP IBCSG Partners Foundation, Takeda | NSCLC, Stage III, ALK-rearrangement | 09/24 | 09/24 | | |
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma |
|
|
| Recruiting | 1/2 | 186 | Europe | RSO-021, Thiostrepton | RS Oncology LLC | Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant | 04/25 | 04/25 | | |
| Recruiting | 1/2 | 359 | Europe, Canada, Japan, US, RoW | NVL-520 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 265 | Europe, US, RoW | EP0031 | Ellipses Pharma | Advanced Solid Tumor | 12/26 | 06/27 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 1 | 38 | Europe | Tepotinib, Pembrolizumab, MK-3475 | Institute of Cancer Research, United Kingdom, Merck Healthcare KGaA | Advanced Cancer, Non Small Cell Lung Cancer | 02/28 | 02/28 | | |
NCT01838577: Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study |
|
|
| Active, not recruiting | N/A | 2000 | Europe | | European Organisation for Research and Treatment of Cancer - EORTC | EGFR Mutation Positive Non Small Cell Lung Cancer | 12/21 | 03/22 | | |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Cancer | 03/27 | 03/27 | | |
| Addeo, Alfredo |
| Active, not recruiting | 2 | 12 | Europe | Atezolizumab, Tecentriq | Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Istituto Cantonale di Patologia, Clinical Trial Unit Ente Ospedaliero Cantonale | NSCLC Stage IV | 01/23 | 12/24 | | |
| Recruiting | 2 | 90 | Europe | Durvalumab, Radiotherapy | Swiss Group for Clinical Cancer Research | Non-small Cell Lung Cancer, NSCLC | 12/25 | 12/31 | | |
IePRO, NCT05530187: ePRO-based Model of Care to Manage and Monitoring Symptoms of Cancer Patients Treated With Immune Checkpoint Inhibitors |
|
|
| Recruiting | 2 | 198 | Europe | Electronic Patient-reported Outcomes-based Model of Care | Manuela Eicher | Patient Reported Outcome Measures, Patient Safety | 11/23 | 11/23 | | |
| Recruiting | 2 | 60 | Europe | Amivantamab, Lazertinib, Zirabev | ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals | Non Small Cell Lung Cancer | 03/26 | 09/26 | | |
| Recruiting | 2 | 96 | Europe | Durvalumab, Imfinzi, Carboplatin, Paclitaxel, Stereotactic body radiation therapy (SBRT), Surgical resection - definitive local treatment., Radical radiotherapy - definitive local treatment., Tremelimumab | ETOP IBCSG Partners Foundation, AstraZeneca | Non-small Cell Lung Cancer, Stage IV, Oligometastasis | 08/26 | 12/26 | | |
AMBER, NCT06068153: AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC |
|
|
| Withdrawn | 2 | 47 | Europe | Sotorasib, Lenvatinib | ETOP IBCSG Partners Foundation, Amgen, Eisai Inc. | Metastatic Non Small Cell Lung Cancer, KRAS G12C | 09/26 | 12/26 | | |
SAKK 15/19, NCT04472949: Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). |
|
|
| Active, not recruiting | 2 | 46 | Europe | Durvalumab, MEDI4736, carboplatin, etoposide, Thoracic radiotherapy | Swiss Group for Clinical Cancer Research | Small Cell Lung Cancer, Lung Cancer | 12/27 | 12/27 | | |
| Suspended | N/A | 100 | RoW | Osimertinib | Sheba Medical Center, AstraZeneca | Carcinoma, Non-Small-Cell Lung, Genes, erbB-1 | 09/24 | 09/24 | | |
